CVS Health (NYSE: CVS) on Wednesday reported fourth-quarter financial results that were stronger than what analysts had anticipated. The company reported earnings of $1.73 per share on revenues of $66.9 billion.
The upbeat results pushed the stock 1.7% higher immediately following the announcement. The stock, which fell to a 7-year-low mid-last year, has been slowly recuperating on the hopes that the company’s adoption of a technology-driven business model would help it better compete with the online counterparts.
Since the beginning of 2020, the stock has grown 9%.
Pharmacy Services, the segment that provides pharmacy benefit management services and accounts for about two-thirds of total revenues, grew 6.2% during the quarter, providing ample fillip to the topline.
CEO Larry Merlo said in a statement, “We are confident that we’re on the right path to delivering significant value for all our stakeholders, which is a testament to the efforts of the nearly 300,000 CVS Health employees who work tirelessly to deliver these results while staying true to our purpose of helping people on their path to better health.”
READ: Aurora Cannabis (ACB) likely to post a narrower loss in Q2
Guidance disappoints
Meanwhile, the strong results were partly offset by its guidance which were lower than what analysts had estimated.
Fellow drug-retailer Walgreens Boots Alliance Inc. (NASDAQ: WBA) had a dismal start to its new fiscal year. A report published by the company last month revealed a 6% drop in first-quarter earnings to $1.37 per share on revenues of $34.3 billion.
Most Popular
IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated
IPO News: What to look for when Elevation Oncology makes its Wall Street debut
The healthcare sector is going through a phase of consolidation, creating fresh opportunities for emerging companies in a market that is slowly recovering from the pandemic. Several pharmaceuticals firms have
American Airlines (AAL): Here’s what may or may not work for this airline stock
Shares of American Airlines Group (NASDAQ: AAL) have gained 42% since the beginning of this year and 50% over the past 12 months. Despite this, there is a mixed sentiment
